

Serial No.: 10/805,881  
Attorney Docket No.: 800812-0005

IFW

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Inventor(s) : Ibert C. Wells  
Serial No. : 10/805,881  
Filing Date : March 22, 2004  
Title : METHOD FOR DETECTING DEFICIENT CELLULAR  
MEMBRANE TIGHTLY BOUND MAGNESIUM FOR DISEASE  
DIAGNOSES  
Group Art Unit : 1644  
Examiner : Szperka, Michael Edward.  
Confirmation No. : 9725  
Atty. Docket No. : 800812-0005

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

In accordance with 37 C.F.R. § 1.56 and § 1.97(b), the references listed below and on the attached Form PTO/SB/08A (Substitute for Form 1449A-B/PTO) are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. Copies of the cited documents are enclosed. Submission of these references is not an admission that the references constitute prior art.

**U.S. PATENTS**

Patent No.	Inventor(s)	Issue Date
None.		

**FOREIGN PATENTS**

Country	Patent No./Publication No.	Publication Date
None.		

**Certificate of Mailing Under 37 C.F.R. 1.8**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450, on:

Date: Nov. 10, 2005  
Signature: Lora Gurley  
Printed Name: Lora Gurley

The Director is hereby authorized to charge any additional amount required, or credit any overpayment, to Deposit Account No. 19-4409.

**OTHER REFERENCES**

See attached Form PTO/SB/08B.


Applicant respectfully requests that these references be made of record in the above-identified application and considered by the Examiner during prosecution of the application.


It is respectfully submitted that the present invention as claimed is patentable over the listed references.

This information disclosure statement is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114. Accordingly, no fee is due.

Acknowledgment of receipt is respectfully requested.

Respectfully submitted,

By:   
Nancy T. Morris, Reg. No. 42,017  
STINSON MORRISON HECKER LLP  
1201 Walnut Ste 2800  
Kansas City MO 64106-2150  
Telephone: (816) 842-8600  
Facsimile: (816) 691-3495  
Attorney for Applicant



Substitute for Form 1449B (Modified) <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number:	10/805,881
		Filing Date:	03/22/04
		First Named Inventor:	Ibert C. Wells
		Group Art Unit:	9725
Examiner Name:	Szperka, Michael Edward		
Attorney Docket Number:	800812-0005		
Sheet	1	of	2

OTHER REFERENCES – NON PATENT LITERATURE DOCUMENTS AND INFORMATION			
Examiner Initials*	Cite No.¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
		MADSEN, S. Nistrup, et al. (1973) <i>Insulin Response to Oral Glucose in Patients with Preeclampsia</i> (Danish Medical Bulletin) 20(1)13-15	
		ROBERTS, James M., et al. (1991) <i>Clinical and Biochemical Evidence of Endothelial Cell Dysfunction in the Pregnancy Syndrome Preeclampsia</i> (American Journal of Hypertension, Ltd.) 4:700-708	
		ROBERTS, JAMES M., et al. (1993) <i>Pre-eclampsia: more than pregnancy-induced hypertension</i> (The Lancet) 341:1447-1451	
		SOWERS, JAMES R., et al. (1993) <i>Postpartum Abnormalities of Carbohydrate and Cellular Calcium Metabolism in Pregnancy Induced Hypertension</i> (American Journal of Hypertension, Ltd.) 6:302-307	
		JACOBBER, SCOTT J., et al. (1994) <i>Postpartum Blood Pressure and Insulin Sensitivity in African-American Women With Recent Preeclampsia</i> (American Journal of Hypertension, Ltd.) 7:933-936	
		REITER, LORETTA, et al. (1994) <i>Hypertension in Pregnancy: The Incidence of Underlying Renal Disease and Essential Hypertension</i> (American Journal of Kidney Disease) 24:883-887	
		FUH, MARTIN M. T., et al. (1995) <i>Resistance to Insulin-Mediated Glucose Uptake and Hyperinsulinemia in Women Who Had Preeclampsia During Pregnancy</i> (American Journal of Hypertension, Ltd.) 8(7):768-771	
		KAAJA, RISTO, et al. (1995) <i>Serum Lipoproteins, Insulin, and Urinary Prostanoid Metabolites in Normal and Hypertensive Pregnant Women</i> (Obstetric & Gynecology) 85:353-356	
		SOWERS, JAMES R., et al. (1995) <i>Hyperinsulinemia and Insulin Resistance Are Associated With Preeclampsia in African-Americans</i> (American Journal of Hypertension, Ltd.) 8(1):1-4	
		SIBAI, BAHAM., (1996) <i>Treatment of Hypertension in Pregnant Women</i> (The New England Journal of Medicine) 335:257-265	
		DEKKER, GUSTAAF A., et al. (1998) <i>Etiology and pathogenesis of preeclampsia: Current concepts</i> (Am J Obstet Gynecol) 1359-1375	
		KAAJA, RISTO., (1998) <i>Insulin Resistance Syndrome in Preeclampsia</i> (Seminars in Reproductive Endocrinology) 16(1):41-46	
		ROBERTS, JAMES M. (1999) <i>Objective Evidence of Endothelial Dysfunction in Preeclampsia</i> (American Journal of Kidney Diseases) 33:992-997	
		ROBERTS, J. M., et al. (2001) <i>Pathogenesis and genetics of pre-eclampsia</i> (The Lancet) 357:53-56	
		MCGARRY J. DENNIS (2001) <i>Dysregulation of Fatty Acid Metabolism in the Etiology of Type 2 Diabetes</i> (Diabetes) 51:7-18	
		WOLF, MYLES, et al. (2002) Press Release from Massachusetts General Hospital, <i>Simple blood test may be able to predict risk of preeclampsia</i>	
		MYERS, JENNY E., et al. (2002) <i>Hypertensive Diseases and Eclampsia</i> , (Obstetrics and Gynecology) 14:119-125	
		MANCO-JOHNSON, M. J., et al. (1994) Abstract ONLY from <i>Hyperglycemia-induced hyperinsulinemia decreases material and fetal plasma protein C concentration during ovine gestation</i> (Pediatr-Res) 36(3):293-299	

		DEKKER, G. A., et al. (1995) Page 1042 ONLY from <i>Underling disorders associated with severe early-onset preeclampsia</i> (Am J Obstet Gynecol) 173:1042-1048	
		STONESTREET, B. S., et al. (1995) Abstract ONLY from <i>Circulatory and metabolic effects of hypoxia in the hyperinsulinemic ovine fetus</i> (Pediatr-Res) 38(1):67-75	
		LAIVUORI, H., et al. (1996) Abstract ONLY from <i>Hyperinsulinemia 17 years after preeclamptic first pregnancy</i> (J Clin Endocrinol Metab) 81(8):2908-2011S	
		MARTINEZ, A.E., et al. (1996) Abstract ONLY from <i>Hyperinsulinemia in glucose-tolerant women with preeclampsia. A controlled study.</i> (American Journal of Hypertension, Ltd.) 9(6):610-614	
		STONESTREET, B. S., et al. (1996) Abstract ONLY from <i>Circulatory and metabolic effects of alpha-adrenergic blockade in the hyperinsulinemic ovine fetus</i> (J Soc Gynecol Investig.) 3(5):241-249	
		CHRISTESEN, H. B., et al. (1998) Abstract ONLY from <i>Prolonged elimination of tolbutamide in a premature newborn with hyperinsulinaemic hypoglycaemia</i> (Eur J Endocrinol) 138(6):698-701	
		PORTER, S. E., et al. (1998) Abstract ONLY from <i>Progressive pancreatic islet hyperplasia in the islet-targeted, parathyroid hormone-related protein-overexpressing mouse</i> (Endocrinology) 139(9):3743-3751	
		ROACH, V. J., et al. (1998) Abstract ONLY from <i>Evaluation of glucose intolerance in pregnancy using biochemical markers of fetal hyperinsulinemia.</i> (Gynecol Obstet Invest.) 45(3):174-176	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.  
 Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.  
 DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.